Protocol for a qualitative mechanistic study of MDMA with a sample of psychoanalytic psychotherapists: A phenomenological investigation Authors: Elisa Liberati, H. Valerie Curran, Peter Fonagy, Henry Clements, Alessandra Lemma, Rosalind McAlpine, David J. Nutt, Anne Katrin Schlag, Sunjeev K. Kamboj, Luca Aquili, Luca Aquili, Luca Aquili Published: 2026 ABSTRACT IntroductionMethylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AP) is a potentially transformative intervention for post-traumatic stress disorder (PTSD). Despite encouraging Phase III trial results, the psychological mechanisms underpinning MDMA’s therapeutic effects remain insufficiently understood. Existing research on MDMA has emphasised neurobiological processes but has not adequately incorporated subjective, relational, and experiential processes that are likely to be central to optimising psychedelic-assisted treatments. In the absence of an established clinical psychological theory of MDMA-AP, qualitative approaches can support theory development to refine and optimise MDMA-AP, and identify cross-diagnostic change processes that may broaden its therapeutic scope.Materials and methodsApproximately 25 experienced psychodynamically trained psychotherapists will receive two doses of MDMA (80–120 mg, oral), separated by ≥1 week, under controlled research conditions in an open-label, qualitative mechanistic study. Clinician-participants will complete baseline interviews examining beliefs and attitudes toward MDMA-AP, brief phenomenological interviews during MDMA sessions, in-depth phenomenological and theory-oriented follow-up interviews examining experience and understandings of MDMA-associated change processes, and daily reflective journals between dosing sessions. Additional standardised measures will assess reflective functioning and related constructs. Qualitative data will be analysed using phenomenological and thematic approaches, and grounded theory-inspired techniques will be used to develop a theoretically coherent model of MDMA’s psychological mechanisms of action grounded in the full dataset.DiscussionIn this study of MDMA’s potential mechanisms-of-action, we treat psychotherapists as expert observers of their own psychological processes. By examining first-hand experience in participants selected for their well-developed capacity for self-reflection, meta-awareness, and advanced theoretical and clinical frameworks for understanding mental phenomena, psychopathology, and psychological treatment, we anticipate generating novel insights into MDMA’s therapeutic mechanisms-of-action. The primary study output will be a theoretically grounded model of MDMA’s psychological mechanisms of action, intended to inform novel treatment models amenable to future experimental evaluation. The study also offers a transferable framework for qualitative mechanistic investigations of psychedelic compounds, supporting the development of integrative and evidence-based models of psychedelic therapy. 1. Introduction Psychedelic-assisted psychotherapy has re-emerged as a highly promising strategy for treating a range of psychiatric disorders [1, 2]. Among psychedelic compounds, the evidence base relating to the entactogen MDMA is particularly advanced, with two Phase III trials supporting its efficacy and safety in post-traumatic stress disorder (PTSD) [3,4]. Yet, despite meeting or exceeding the typical requirements for a treatment to be considered empirically supported, the US Food and Drug Administration (FDA) did not approve a new drug application for MDMA-assisted psychotherapy (MDMA-AP) in 2024, citing various limitations of the relevant MDMA-AP trials. Additionally, the role of the non-pharmacological components of MDMA-AP and related psychedelic treatments remains uncertain [5,6]. Existing trial designs – which typically compare MDMA + psychotherapy with placebo + psychotherapy – do not disentangle drug from psychotherapy effects. Moreover, because the FDA does not regulate psychotherapy, a key component of the proposed treatment falls outside of current regulatory processes. Additionally, some researchers have questioned the necessity of co-administered psychotherapy in psychedelic assisted psychotherapies [5]. In the case of MDMA-AP, scepticism regarding the psychotherapy component may be driven, in part, by the relative unfamiliarity of psychotherapy researchers with the inner-directed therapy model used in the main trials [3,4,7], which draws on components of somatic and internal family systems psychotherapies [8–10]. Although other models of psychotherapy have also been proposed as adjuncts to MDMA treatments, these are often narrowly based around cognitive behavioural conceptualisations of psychopathology [11] and continue to focus on PTSD [cf. 12]. Indeed, cognitive behavioural therapy has been proposed as a default mode of therapy in psychedelic-psychotherapy combinations by Yaden and colleagues [13]. These authors’ suggestion that cognitive behavioural (and related) therapies should be considered the default, however, relied on somewhat outmoded caricatures of alternative models of psychotherapy (particularly psychoanalysis). Moreover, their suggestions appear grounded in component-level descriptions of therapeutic strategies and their interactions with psychedelics (e.g., “openness, awareness, and engagement could conceivably potentiate psychedelic sessions” [13], p.7), rather than process-level mechanistic explanations of how MDMA might interact (additively or synergistically) with these components. Such process-focused explanations might be exemplified by statements like “MDMA-induced reductions in defensive avoidance may alter the participant’s epistemic stance – for example, by promoting a more trusting attitude towards their therapist – thus encouraging therapeutic engagement and enabling other change processes, like reconsolidation-updating or extinction of traumatic memories”. In the absence of more precisely specified mechanistic hypotheses of this kind, it is difficult to determine how (or which of) these interactions should be tested experimentally and statistically. As such, we believe the proposal for cognitive behavioural therapy primacy in psychedelic-assisted psychotherapy is, at least, premature. Current accounts of MDMA’s psychological mechanisms of action focus on descriptive behavioural psychopharmacology, for example, its effects on self-compassion, openness, empathy, and fear responding. While these behavioural or subjective variables may form the components (e.g., mediators) of a mechanistic model of MDMA’s therapeutic effects [14], their temporal dynamics (i.e., causal ordering), relational embedding, and interactions with psychotherapeutic support remain underspecified, making it difficult to formulate discriminating predictions. To summarise, current descriptions of MDMA-induced psychological phenomena remain theoretically underdeveloped and insufficiently integrated into existing theories of psychological change. The lack of a shared lexicon or validated process measures further contributes to the conceptual gaps between descriptive behavioural-psychopharmacological findings, process-oriented psychotherapeutic studies and clinical trial research. Without a well-developed understanding of MDMA’s mechanisms of action, it is difficult to establish which non-pharmacological elements of MDMA-AP are most essential, how these elements might be prioritised and optimised, and which elements (if any) might be unhelpful or even harmful (including, but not limited to, psychotherapeutic modality, relational stance, exposure to traumatic material, dosing-day support, as well as preparation provision and post-dosing meaning-making). These questions are, of course, based on the assumption that at least some psychotherapy is needed in MDMA treatment, which, as noted above, remains a contentious point in psychedelic medicine research [15]. For this study, we devised an innovative qualitative protocol aimed at developing a theory of MDMA’s therapeutic mechanisms of action by investigating its effects in a specific participant group: psychotherapists with verified credentials in psychoanalytic/psychodynamic psychotherapy. Our participants will have limited past experience with MDMA and will be administered the drug in a controlled research setting under clinical supervision. Due to their training – a compulsory component of which is completion of extensive personal therapy – these participants are likely to be highly skilled in self-reflection, to possess an advanced capacity for describing their own cognitive and affective processes, and to be able to apply theoretical frameworks to understand mental phenomena in general, and psychopathology and its treatment in particular. The detailed qualitative exploration of participants’ first-hand experiences of MDMA will, therefore, provide a credible, clinically informed basis for developing a psychological model of MDMA’s action. The objectives of this study are, therefore: To explore the phenomenology of MDMA experience in psychodynamic psychotherapists under controlled research conditions. To explore the phenomenology of MDMA experience in psychodynamic psychotherapists under controlled research conditions. To examine subjectively experienced changes in self-experience and relational patterns. To examine subjectively experienced changes in self-experience and relational patterns. To invite participants to frame these experiences in terms of psychological concepts relevant to theory-building of MDMA–psychotherapy combinations (participants’ spontaneous accounts and theory-oriented formulations will be treated as conceptually distinct and analysed separately). To invite participants to frame these experiences in terms of psychological concepts relevant to theory-building of MDMA–psychotherapy combinations (participants’ spontaneous accounts and theory-oriented formulations will be treated as conceptually distinct and analysed separately). To synthesise insights into a theoretically grounded model of MDMA’s therapeutic mechanisms of action (ideally linking qualitatively generated experiential sequences to operationalisable constructs) and to generate testable hypotheses (e.g., about mediation, moderation and causal pathways) for future clinical and experimental trials. To synthesise insights into a theoretically grounded model of MDMA’s therapeutic mechanisms of action (ideally linking qualitatively generated experiential sequences to operationalisable constructs) and to generate testable hypotheses (e.g., about mediation, moderation and causal pathways) for future clinical and experimental trials. To simulate aspects of the use of MDMA in recent clinical trials [1], participants will receive up to 120 mg MDMA in each of two dosing sessions, separated by at least one week. No formal psychotherapeutic procedures (e.g., those intended to direct trauma or experience processing) will be employed. The study objectives will be achieved through a series of in-depth interviews, narrative journaling, and other psychological assessments before and after the dosing sessions. In addition, brief interviews will be performed during each dosing session. Qualitative data will be analysed using phenomenological approaches and thematic analysis to examine changes in participants’ attitudes, self-experience, emotional processing, and relational patterns across baseline, acute and sub-acute (dosing sessions) phases and follow-up phase. The qualitative findings will be integrated with other data sources (journalling and validated questionnaires) using techniques inspired by grounded theory (such as the constant comparison approach [16]), with a view to producing a theoretically rigorous model of MDMA’s psychological mechanisms of action. 2. Materials and methods 2.1 Study design This is an open-label, single-site, qualitative mechanistic study conducted at an academic psychopharmacology facility. The study has received ethical approval from University College London’s Research Ethics Committee (REC reference 2025-0272-336). 2.2 Sample and recruitment 2.2.1 Rationale for the psychodynamic orientation. We will recruit trained psychodynamic psychotherapists who meet the eligibility criteria. The clinical approach of psychodynamic clinicians is grounded in psychoanalytic theory and emphasises the role of unconscious processes, early relational experiences, and internalised attachment orientations in shaping current thoughts, affect, and behaviours. Central to this orientation are the concepts of transference and countertransference [17]. The latter refers to the therapist’s emotional responses to the patient/participant, which are viewed as an invaluable source of information about the patient/participant’s internal world. Effective psychodynamic practice, therefore, requires therapists to cultivate self-reflective capacities and a willingness to explore their own inner world, so that countertransference can be recognised and used constructively within the therapeutic relationship. This emphasis on self-awareness is reflected in lengthy clinical training that, in combination with mandated personal psychotherapy (usually comprising at least two sessions weekly for several years), is believed to increase meta-awareness and the facility for describing mental states [18,19]. In this respect, the psychodynamic orientation departs from other psychotherapies that are more focused on behavioural change (such as cognitive behavioural therapy) or on empathy and unconditional positive regard (such as humanistic therapy), for which personal therapy is typically not mandated. Our decision to focus on psychodynamic psychotherapists precisely reflects the need for our participants to be highly skilled in self-reflection and to possess a language for describing subjective experience with precision. Although this methodological choice presents other limitations – primarily that participants may be primed to interpret their experiences through a particular theoretical lens – our analysis will deliberately separate description of first-hand experience from interpretation (these will be elicited through different instruments and at different time-points; see section 3). 2.2.2 Eligibility criteria. As a starting point, inclusion criteria are as follows: Age 25–65 years Age 25–65 years Qualification in psychodynamic psychotherapy obtained through a British Psychoanalytic Council (BPC) or United Kingdom Council for Psychotherapy (UKCP) accredited institution Qualification in psychodynamic psychotherapy obtained through a British Psychoanalytic Council (BPC) or United Kingdom Council for Psychotherapy (UKCP) accredited institution Personal therapy during training comprising ≥2 sessions weekly, delivered by a psychoanalyst or a psychodynamic psychotherapist Personal therapy during training comprising ≥2 sessions weekly, delivered by a psychoanalyst or a psychodynamic psychotherapist ≥ 5 years post-qualification ≥ 5 years post-qualification Exclusion criteria include: MDMA use in the past five years MDMA use in the past five years Regular psychedelic use in the past Regular psychedelic use in the past Psychiatric disorder Psychiatric disorder Use of psychotropic medication Use of psychotropic medication Metabolic or cardiovascular disease Metabolic or cardiovascular disease Neurological conditions Neurological conditions Pregnancy or breastfeeding Pregnancy or breastfeeding BMI < 18 or >30 kg/m² BMI < 18 or >30 kg/m² Any abnormal finding at the health assessment Any abnormal finding at the health assessment We aim to recruit approximately 25 individuals. The sample size is informed by the concept of information power [20], which suggests that the more information a sample holds that is relevant to the study aim, the fewer participants are required. Given the multiple data-collection points per participant, the diversity of data sources (interviews, questionnaires, journals), and the specific characteristics of the targeted population, we anticipate that a pragmatic sample size of approximately n = 25 will generate sufficient data to meet the study aims, reach meaning saturation [21], and permit meaningful comparisons across participants without incurring data waste. Recruitment will be via British Psychoanalytic Council registers, training institutions, specialist conferences, professional networks, and word of mouth. It is possible that some of the above criteria (other than those required for safe drug administration) may need to be relaxed if recruitment efforts indicate they are overly restrictive. Any changes to eligibility criteria or other aspects of the protocol described here will be reviewed through a formal amendment to the Research Ethics Committee and implemented only following their approval. 2.3 Study procedures Eligible participants who decide to take part will provide written informed consent in line with the principles expressed in the Declaration of Helsinki. Participants will then complete five sessions plus longitudinal journaling (see Fig 1). Study flowchart. Session timelines and assessments. RAP: Relational Anecdote Paradigm. Physiological measures will consist of EKG (electrocardiograph) at baseline and periodic HR (heart rate), BP (blood pressure) and Temp (skin temperature) on Sessions 2 and 3. Periodic assessment of subjective drug effects will use the Drug Effects Questionnaire (DEQ) and Positive and Negative Affect Schedule (PANAS) short-form. Note: The possible additional micro-phenomenology interview (potentially in Session 4) is not shown. Session 1 (Baseline data collection and preparation for dosing). After the online screening and follow-up telephone pre-screening, Session 1 includes an additional health screening and final confirmation of eligibility. Baseline psychological questionnaires, baseline Relational Anecdote Paradigm (RAP) interview, baseline thematic interview, and preparation for the dosing sessions will also be completed on Session 1. The health screening includes a 6-lead EKG and blood pressure assessment. Findings will be reviewed by a medical doctor or a research nurse prior to participation in Session 2 (first dosing session). Given the multiple data collection points in this session, researchers will ensure flexible timing and plan breaks to reduce participant burden. Preparation for the dosing session covers ‘setting’, explanations about the psychological and physiological effects of MDMA, timing of phenomenological interviews, and agreements concerning music, use of eyeshades, and touch (limited to participant-initiated hand-holding). Session 1 (Baseline data collection and preparation for dosing). After the online screening and follow-up telephone pre-screening, Session 1 includes an additional health screening and final confirmation of eligibility. Baseline psychological questionnaires, baseline Relational Anecdote Paradigm (RAP) interview, baseline thematic interview, and preparation for the dosing sessions will also be completed on Session 1. The health screening includes a 6-lead EKG and blood pressure assessment. Findings will be reviewed by a medical doctor or a research nurse prior to participation in Session 2 (first dosing session). Given the multiple data collection points in this session, researchers will ensure flexible timing and plan breaks to reduce participant burden. Preparation for the dosing session covers ‘setting’, explanations about the psychological and physiological effects of MDMA, timing of phenomenological interviews, and agreements concerning music, use of eyeshades, and touch (limited to participant-initiated hand-holding). Sessions 2 and 3 (Dosing and acute/sub-acute data collection): These sessions include oral administration of 80–120 mg MDMA, physiological monitoring, acute-phase monitoring questionnaires, and brief phenomenological interviews during the acute and sub-acute exposure phases. Our decision to include two dosing sessions was informed by a desire to simulate the multiple dosing typically used in clinical trials of MDMA-AP (typically three dosing sessions, e.g., [3,4]), while ensuring participant burden is minimised. Sessions 2 and 3 (Dosing and acute/sub-acute data collection): These sessions include oral administration of 80–120 mg MDMA, physiological monitoring, acute-phase monitoring questionnaires, and brief phenomenological interviews during the acute and sub-acute exposure phases. Our decision to include two dosing sessions was informed by a desire to simulate the multiple dosing typically used in clinical trials of MDMA-AP (typically three dosing sessions, e.g., [3,4]), while ensuring participant burden is minimised. During dosing, the researchers’ stance will be supportive and non-directive. Support will comprise physiological monitoring, response to practical needs, verbal reassurance, and, at the participant’s request, basic grounding techniques such as guided slow breathing or hand-holding, intended to manage acute episodes of distress or fulfil participants’ expressed need for safety or comfort. If distressing material arises spontaneously, researchers will acknowledge this with empathy and warmth, without interpretation, reappraisal, or any other psychotherapeutic technique. Participants will be gently redirected to present-moment phenomenology. Sessions 2 + 1 day and 3 + 1 day (Post-acute data collection): These assessments are designed to be relatively low-burden question(naire)s completed online. Except for an assessment of current affect, the question(naire)s refer to participants’ retrospective response to the dosing session (see Table 1). 10.1371/journal.pone.0350728.t001Table 1Candidate psychological constructs (elements of candidate mechanisms of action) and corresponding data collection tools.PhaseRelevant psychological constructData collection methodBaselineN/AGeneral thematic interview (prior attitudes, beliefs and ideas regarding MDMA and MDMA-AP).Acute and sub-acute (dosing session)Embodied experience/shiftsBrief phenomenological interviews.Drug Effects Questionnaire (DEQ).Physiological measures.Cognitive experience/shiftsBrief phenomenological interviews.Affective experience/shiftsBrief phenomenological interviews.Positive & Negative Affect Schedule (PANAS-SF).Imagery experience/shiftsBrief phenomenological interviews.Post-acute(1d post dosing)Affective experience/shiftsPANAS-SF.Response to music (during dosing)Geneva Emotional Music Scale.Bespoke music-related ratings.Self-related processesSense of Self Scale.Emotion confrontation/resolutionEmotional Breakthrough Inventory (EBI).Altered consciousness5-Dimensional Altered States of Consciousness Scale (5D-ASC).Challenging experiencesChallenging Experiences Questionnaire (CEQ).Follow-upSelf-related processesIn-depth phenomenological interview.Relational Anecdote Paradigm (RAP) interview.Sussex-Oxford compassion scales (SOCS-Self).Self-other processing and relational experiencesIn-depth phenomenological interview.RAP interview.SOCS-Other.Epistemic Trust Questionnaire (ETQ-15). Experience Close Relationships Scale (ECR-36).Inventory of Interpersonal Problems (IIP-32).Epistemic stanceETQ-15.Reflexive functioningRAP interview.Defence mechanismsIn-depth phenomenological interview.RAP interview.Compassion (towards self & other)SOCS-Self and SOCS-Other.EmpathyToronto Empathy Questionnaire (TEQ).N/AFollow-up thematic interview (post-experience theoretical integration). Candidate psychological constructs (elements of candidate mechanisms of action) and corresponding data collection tools. Session 4 (Follow-up data collection): This session, conducted remotely (via videoconferencing), includes a follow-up RAP interview, psychological questionnaires, and an in-depth qualitative interview. If a micro-phenomenological interview is included, it will take place on Session 4. Session 4 (Follow-up data collection): This session, conducted remotely (via videoconferencing), includes a follow-up RAP interview, psychological questionnaires, and an in-depth qualitative interview. If a micro-phenomenological interview is included, it will take place on Session 4. Session 5 (Follow-up data collection): Like Session 4, this session is conducted remotely and includes a follow-up thematic interview inviting theoretical integration of the MDMA experience and views on its mechanism of action in MDMA-AP. The interview will also cover participants’ perspectives on music during their experience, and more broadly, in MDMA-AP. Session 5 (Follow-up data collection): Like Session 4, this session is conducted remotely and includes a follow-up thematic interview inviting theoretical integration of the MDMA experience and views on its mechanism of action in MDMA-AP. The interview will also cover participants’ perspectives on music during their experience, and more broadly, in MDMA-AP. Journaling: Participants will be asked to prepare brief daily written or audio reflections from three days before Session 2 until three days after Session 3. Journaling: Participants will be asked to prepare brief daily written or audio reflections from three days before Session 2 until three days after Session 3. 2.4 Medicinal product MDMA is provided by PharmAla Biotech (Canada) in 40 mg capsules. Based on recommendations from recent clinical and experimental studies of MDMA, we will administer a total dose of up to 120 mg per session on two sessions separated by ≥1 week (see also Section 2.7 for rationale for the dose). As is typical of clinical trials, an initial 80 mg dose will be followed by a top-up dose of 40 mg after approximately 90 minutes if the participant consents and tolerates the lower dose well. This split-dosing protocol extends the duration of action of MDMA while avoiding a rapid peak effect (as might be expected from a 120 mg bolus). If the participant does not wish to proceed with the top-up dose, or if there are concerns about tolerability in either dosing session, the lower (80 mg) will be the final recorded dose for that session. This flexibility in dosing was deemed appropriate by the FDA in the two largest Phase III clinical trials of MDMA for PTSD, in recognition of uncertainty regarding the optimal dose [1]. Participants’ physiological and psychological responses will be closely monitored throughout the dosing session (approximately 8 h). Harmful or unpleasant responses will be monitored and documented throughout the dosing session. Attributability of these responses to MDMA will be determined by the supervising medical professional and categorised as mild (no impact on daily activities), moderate (some interference with daily activities), or severe (prevents daily activities), and as anticipated or unanticipated. Drug transport, handling, and storage procedures will comply with the conditions set out under the research unit’s Schedule I controlled drug licence granted by the relevant UK government department (the Home Office). Access to the controlled-drug storage facility at University College London is strictly controlled, and robust documentation procedures for drug handling are in place and subject to regular Home Office inspections. 2.5 Data collection tools 2.5.1 Qualitative interviews. We will use several forms of semi-structured qualitative interviews to capture participants’ experience-near descriptions of MDMA effects, reflective meaning-making, and theory-driven interpretations at different points across study phases, as outlined in Table 1. A)Phenomenological interviews will be used to explore participants’ first-hand experience and sense-making of the dosing sessions.Brief phenomenological interviews (10–20 min) are planned during each dosing session at approximately t = 1.5 h, 3 h, and 5 h, and at the end of the session (t ≈ 7 h). These interviews will encourage participants to attend to their experience in the here-and-now and to describe changes in thoughts, feelings, bodily sensations, embodied experience, and mood as drug effects unfold. The frequency and timing may be adjusted based on early participants’ feedback and acceptability; for example, the number of interviews may be reduced.An Interpretative Phenomenological Analysis (IPA) interview [22] will be conducted in Session 4 (after completion of the second dosing session) to elicit participants’ experience and meaning-making of the MDMA sessions. As with the brief phenomenological interviews, the focus will remain on experience-near accounts, and participants will also be invited to elaborate their interpretation and meaning-making of the MDMA experiences. The interviewer will additionally explore changes in specific domains, including sense of self and self–other experience.A micro-phenomenological interview [23] may be incorporated into Session 4 for some participants, depending on whether preliminary findings suggest that this additional detailed procedure is justified (i.e., is not excessively burdensome and is likely to yield significant additional phenomenological insights not obtained from IPA interviews). This method supports heightened awareness and precise description of a re-evoked experience. Rather than structuring the exchange around topic-based questions, the interview aims to orient participants’ attention to moment-to-moment features of the re-evoked event. Here, the objective is to obtain a detailed account of the moment participants become aware of MDMA effects, focusing on the procedural, embodied dimension of experience. This approach is intended to identify aspects that may remain implicit or unfold at a pre-reflective level. Phenomenological interviews will be used to explore participants’ first-hand experience and sense-making of the dosing sessions. Brief phenomenological interviews (10–20 min) are planned during each dosing session at approximately t = 1.5 h, 3 h, and 5 h, and at the end of the session (t ≈ 7 h). These interviews will encourage participants to attend to their experience in the here-and-now and to describe changes in thoughts, feelings, bodily sensations, embodied experience, and mood as drug effects unfold. The frequency and timing may be adjusted based on early participants’ feedback and acceptability; for example, the number of interviews may be reduced. Brief phenomenological interviews (10–20 min) are planned during each dosing session at approximately t = 1.5 h, 3 h, and 5 h, and at the end of the session (t ≈ 7 h). These interviews will encourage participants to attend to their experience in the here-and-now and to describe changes in thoughts, feelings, bodily sensations, embodied experience, and mood as drug effects unfold. The frequency and timing may be adjusted based on early participants’ feedback and acceptability; for example, the number of interviews may be reduced. An Interpretative Phenomenological Analysis (IPA) interview [22] will be conducted in Session 4 (after completion of the second dosing session) to elicit participants’ experience and meaning-making of the MDMA sessions. As with the brief phenomenological interviews, the focus will remain on experience-near accounts, and participants will also be invited to elaborate their interpretation and meaning-making of the MDMA experiences. The interviewer will additionally explore changes in specific domains, including sense of self and self–other experience. An Interpretative Phenomenological Analysis (IPA) interview [22] will be conducted in Session 4 (after completion of the second dosing session) to elicit participants’ experience and meaning-making of the MDMA sessions. As with the brief phenomenological interviews, the focus will remain on experience-near accounts, and participants will also be invited to elaborate their interpretation and meaning-making of the MDMA experiences. The interviewer will additionally explore changes in specific domains, including sense of self and self–other experience. A micro-phenomenological interview [23] may be incorporated into Session 4 for some participants, depending on whether preliminary findings suggest that this additional detailed procedure is justified (i.e., is not excessively burdensome and is likely to yield significant additional phenomenological insights not obtained from IPA interviews). This method supports heightened awareness and precise description of a re-evoked experience. Rather than structuring the exchange around topic-based questions, the interview aims to orient participants’ attention to moment-to-moment features of the re-evoked event. Here, the objective is to obtain a detailed account of the moment participants become aware of MDMA effects, focusing on the procedural, embodied dimension of experience. This approach is intended to identify aspects that may remain implicit or unfold at a pre-reflective level. A micro-phenomenological interview [23] may be incorporated into Session 4 for some participants, depending on whether preliminary findings suggest that this additional detailed procedure is justified (i.e., is not excessively burdensome and is likely to yield significant additional phenomenological insights not obtained from IPA interviews). This method supports heightened awareness and precise description of a re-evoked experience. Rather than structuring the exchange around topic-based questions, the interview aims to orient participants’ attention to moment-to-moment features of the re-evoked event. Here, the objective is to obtain a detailed account of the moment participants become aware of MDMA effects, focusing on the procedural, embodied dimension of experience. This approach is intended to identify aspects that may remain implicit or unfold at a pre-reflective level. B)A modified Relationship Anecdote Paradigm (RAP) interview will be conducted in Sessions 1 and 4. Participants will be asked to recall a small number of interactions between themselves and another person (including friends, primary caregivers, and their psychotherapists). For each interaction, participants will be asked contextual questions (e.g., when, with whom), questions about their own and the other’s statements, behaviours, and reactions, and to describe how the episode concluded. At the end of the exercise, participants will be asked to recall two events that are memorable because of their characteristics: one described as an unpleasant interaction that they sometimes replay and wish had not happened, and one described as a pleasant interaction that forms a happy memory. A modified Relationship Anecdote Paradigm (RAP) interview will be conducted in Sessions 1 and 4. Participants will be asked to recall a small number of interactions between themselves and another person (including friends, primary caregivers, and their psychotherapists). For each interaction, participants will be asked contextual questions (e.g., when, with whom), questions about their own and the other’s statements, behaviours, and reactions, and to describe how the episode concluded. At the end of the exercise, participants will be asked to recall two events that are memorable because of their characteristics: one described as an unpleasant interaction that they sometimes replay and wish had not happened, and one described as a pleasant interaction that forms a happy memory. The original RAP was devised to support analysis of Core Relationship Conflict Theme (CCRT) and has been described as the first operational method for assessing transference [24]. From a psychodynamic perspective, CCRT reflects a relational template forged in early infancy that informs subsequent close relationships; thus, assessing CCRT at different time points provides one method for examining shifts in well-established relational patterns. RAP interviews have been used in numerous studies and adapted to specific aims, including examination of therapeutic closeness and distance and changes in the therapeutic relationship in relation to outcomes [25,26]. In the present study, RAP material will support examination of changes in reflective functioning [27], relational patterns (via CCRT), and, qualitatively, changes in the content and quality of recalled episodes before and after MDMA exposure. C)Thematic interviews will explore participants’ knowledge of, and attitudes toward, MDMA-AP and MDMA as a potential therapeutic agent. These interviews will be conducted prior to and after the dosing sessions (Sessions 1 and 5) to evaluate changes in attitudes and understanding. In Session 5, the thematic interview will also invite participants to conceptualise their first-hand MDMA experiences using psychological concepts relevant to theory building and intervention development. Thematic interviews will explore participants’ knowledge of, and attitudes toward, MDMA-AP and MDMA as a potential therapeutic agent. These interviews will be conducted prior to and after the dosing sessions (Sessions 1 and 5) to evaluate changes in attitudes and understanding. In Session 5, the thematic interview will also invite participants to conceptualise their first-hand MDMA experiences using psychological concepts relevant to theory building and intervention development. 2.5.2 Questionnaires. Stable traits will be assessed using validated questionnaires administered during Sessions 1 and 4 to evaluate changes in: compassion toward self and others (Sussex-Oxford Compassion Scales (20 items each for self- and other-) [28]), empathy (Toronto Empathy Questionnaire [29]), epistemic trust (The Epistemic Trust Questionnaire (ETQ-15) [30]), attachment patterns (Experiences in Close Relationships Revised Scale (36 items) [31]), and interpersonal problems (Inventory of Interpersonal Problems (IIP, 32 items) [32]). Acute subjective drug response will be assessed using two brief self-report ‘response to dosing questionnaires’ (Fig 1): the Positive and Negative Affect Schedule-Short Form (PANAS-SF; [33]) and the Drug Effects Questionnaire (DEQ; [34]) at t = 0 (pre-drug baseline) and t = 0.5 h, 1.5 h, 3 h, 4.5 h, and 5.5 h post-drug on each dosing session. A post-acute evaluation of participants’ response to the dosing session will be conducted the day after each dosing session remotely via an online survey. Apart from repeating the PANAS-SF, which refers to current affect, the other question(naire)s completed on Session 2 + 1d and Session 3 + 1d refer to participants’ experiences of the dosing procedure: Emotional Breakthrough Inventory (EBI: [35]), 5-Dimensional Altered States of Consciousness (5D-ASC; [36]), Challenging Experience Questionnaire, 7-item [37] and Geneva Emotional Music Scale [38]. Additional bespoke ratings will be obtained regarding the interaction between the music and MDMA. 2.5.3 Physiological measures. Non-invasive measures of blood pressure, heart rate, and body temperature will be taken at intervals during dosing sessions. 2.5.4 Reflective journals. Participants will complete a brief daily journaling task (via a bespoke bot designed for this study, on a secure mobile app) during their involvement in the research. They will be asked to provide a reflective overview of the day’s thoughts and feelings (the task should take no longer than 3–5 minutes daily). Depending on the interval between Sessions 2 and 3, participants will journal for a minimum of 13 days and a maximum of 20 days. 2.6 Data analysis plan 2.6.1 Interviews. All interviews will be recorded and transcribed verbatim. The analysis may be supported by software such as QSR NVIVO. A)Phenomenological interviews. These will be conducted as experience-near brief interviews during dosing sessions, as well as more in-depth interviews at follow-up. The interviews will be analysed using IPA principles as outlined by Smith and colleagues [22]. IPA is committed to in-depth examination of lived experience, with a focus on participants’ meaning-making and their own language. Following interview transcription, an experienced qualitative researcher will undertake exploratory noting to capture key content and highlight passages that are particularly rich in meaning. Provisional interpretative notes will be developed and iteratively queried during analysis. The researcher will then generate experiential statements, through which initial open interpretations are refined and stabilised. These will be organised thematically and clustered into Personal Experiential Themes. Each participant’s interviews will first be analysed ideographically across time-points to develop a rich account of subjective experience of MDMA as it unfolds over time. These accounts will then be synthesised to generate Group Experiential Themes, integrating patterns across the full qualitative dataset. It is expected that analysis of the brief interviews (conducted during the dosing sessions) will foreground immediate experience over meaning-making, with results being used primarily for temporal anchoring and capturing evolving experience. The analytical focus of the in-depth IPA interviews will be on meaning-making and idiographic depth, as well as experience. Phenomenological interviews. These will be conducted as experience-near brief interviews during dosing sessions, as well as more in-depth interviews at follow-up. The interviews will be analysed using IPA principles as outlined by Smith and colleagues [22]. IPA is committed to in-depth examination of lived experience, with a focus on participants’ meaning-making and their own language. Following interview transcription, an experienced qualitative researcher will undertake exploratory noting to capture key content and highlight passages that are particularly rich in meaning. Provisional interpretative notes will be developed and iteratively queried during analysis. The researcher will then generate experiential statements, through which initial open interpretations are refined and stabilised. These will be organised thematically and clustered into Personal Experiential Themes. Each participant’s interviews will first be analysed ideographically across time-points to develop a rich account of subjective experience of MDMA as it unfolds over time. These accounts will then be synthesised to generate Group Experiential Themes, integrating patterns across the full qualitative dataset. It is expected that analysis of the brief interviews (conducted during the dosing sessions) will foreground immediate experience over meaning-making, with results being used primarily for temporal anchoring and capturing evolving experience. The analytical focus of the in-depth IPA interviews will be on meaning-making and idiographic depth, as well as experience. B)Micro-phenomenological interviews: If micro-phenomenology interviews are included (see Section 2.5.1), the focus of enquiry and analysis will be on fine-grained phenomenological events and processes at specific moments. In line with the approach proposed by Petitmengin [23], analysis will identify recurring experiential patterns or microstructures within participants’ narratives. Transcripts will be segmented into experiential units and examined for sensory modalities, emotional tone, attentional focus, and implicit dynamics. These units will then be abstracted into models or maps of experience. Micro-phenomenological interviews: If micro-phenomenology interviews are included (see Section 2.5.1), the focus of enquiry and analysis will be on fine-grained phenomenological events and processes at specific moments. In line with the approach proposed by Petitmengin [23], analysis will identify recurring experiential patterns or microstructures within participants’ narratives. Transcripts will be segmented into experiential units and examined for sensory modalities, emotional tone, attentional focus, and implicit dynamics. These units will then be abstracted into models or maps of experience. C)Thematic interviews: Using thematic analysis [39], the focus will be on attitudes toward MDMA-AP, changes in such attitudes, and conceptual integration of psychological frameworks to describe MDMA’s potential therapeutic effects. Thematic interviews: Using thematic analysis [39], the focus will be on attitudes toward MDMA-AP, changes in such attitudes, and conceptual integration of psychological frameworks to describe MDMA’s potential therapeutic effects. D)RAP interviews: To assess changes in reflective functioning, each RAP interview will be scored using procedures in the Reflective Functioning Manual [27]. Changes in relational patterns will be examined using the CCRT paradigm [24]. We hypothesise that MDMA may predict changes in CCRT (particularly the wish component), with reflective functioning acting as a moderator. Interview order blinding, independent coding, and periodic calibration will be used to enhance coding accuracy. RAP interviews: To assess changes in reflective functioning, each RAP interview will be scored using procedures in the Reflective Functioning Manual [27]. Changes in relational patterns will be examined using the CCRT paradigm [24]. We hypothesise that MDMA may predict changes in CCRT (particularly the wish component), with reflective functioning acting as a moderator. Interview order blinding, independent coding, and periodic calibration will be used to enhance coding accuracy. 2.6.2 Questionnaires. Given the small sample size and absence of a control group, questionnaire responses will be analysed descriptively (e.g., measures of central tendency and variation). Any inferential analyses will be exploratory and interpreted cautiously, as the study is not designed to test hypotheses regarding the measured psychological constructs. 2.6.3 Journaling. Journal data will be analysed using thematic analysis, with the aim of enriching the developing model of MDMA’s subjective mechanisms. Exploratory quantitative analysis (e.g., valence-based indices) may also be undertaken. 2.6.4 Data synthesis. Following completion of the analyses above, the research team will develop a model of MDMA’s therapeutic mechanisms. Findings from qualitative interviews will be compared across individuals to identify convergence and divergence and to generate hypotheses about factors contributing to these patterns. This work will be informed by the ‘constant comparison’ technique, which supports development of “conceptual frameworks or theories through building inductive analysis from the data” [16] (p. 187). Integrating questionnaires, journaling, and RAP-derived indices will support hypothesis generation linking specific subjective experiences to generalisable psychological processes. This synthesis will culminate in a dynamic model of mechanisms-in-action intended to be amenable to testing in future experimental settings. Table 1 summarises candidate psychological constructs which may be included in the model and data collection techniques through which these will be elicited. 2.7 Patient and public involvement Stakeholder consultations with four psychotherapists (representative of the target sample) were used to refine the data-collection sequence, interview probes, data collection tools, and recruitment strategy. Overall feedback indicated good acceptability of the protocol. Suggested changes were minor and implemented via amendments approved by the UCL Research Ethics Committee. Key changes included: Addition of recruitment avenues (specialist conferences and professional networks). Addition of recruitment avenues (specialist conferences and professional networks). Specification of contingency plans if recruitment proved difficult (e.g., removing a seniority criterion from eligibility criteria). MDMA-AP. Specification of contingency plans if recruitment proved difficult (e.g., removing a seniority criterion from eligibility criteria). MDMA-AP. Rewording and addition of interview prompts. Rewording and addition of interview prompts. Rewording of the Participant Information Leaflet to emphasise flexibility in scheduling experimental sessions. Rewording of the Participant Information Leaflet to emphasise flexibility in scheduling experimental sessions. Recognising the potential risk of adverse residual (post-acute) effects of MDMA on participants’ work schedules and clinical commitments at higher doses, we decided to limit the maximum per-session dose to 120 mg. We also decided to have a relatively short minimum interval between dosing sessions (one week) as this was deemed to provide greater flexibility to participants. 2.8 Safety considerations Safety will be ensured through screening, on-site health assessment, on-site physician or research nurse oversight, physiological monitoring, and adverse-event protocols. We will use conservative eligibility criteria to minimise the likelihood of adverse cardiac effects. Eligibility will be evaluated through two stages of screening (online and telephone) and an on-site health assessment in Session 1, including 6-lead EKG and BP assessment, to confirm medical suitability for MDMA administration. Screening results, EKG, and BP readings will be reviewed by a medical doctor or research nurse prior to Session 2, at which point EKG and BP will be re-assessed. Abnormalities detected in Session 1 will lead to exclusion; participants will be informed of the reason for exclusion and advised to monitor BP and/or consult their family doctor as appropriate. A medical doctor or research nurse will supervise drug administration and will be present during the initial 120 min post-administration to monitor physiological responses. Each dosing session will be facilitated by up to two trained researchers, or by a trained researcher and trainee under the supervision of an experienced researcher. We plan to perform assessments of participants’ physiological responses at pre-specified intervals: baseline (pre-dose), t = 30, 45, and 60 min, then at 30-min intervals until t = 180 min, after which monitoring will be hourly. If this interferes with the participants’ immersion in the experience, the number of assessments may be reduced (although baseline, peak and end-point assessments will be retained). Participants will remain under direct observation for the full duration of each dosing session. Adverse events that occur during the study period (from the first dosing session to the last data collection session) will be systematically reported. Any researcher involved in direct participant care will be trained by a senior researcher to identify and document adverse events, with actions taken and resolutions recorded and reported to the ethics committee as required. Our protocol specifies clear thresholds for intervention (e.g., when the PI and/or supervising medic should intervene; when the dosing session should be aborted; when emergency services should be enlisted). At least one researcher with first aid training will be present or immediately available. Any serious adverse events will be promptly reported to the study medic (who will remain on call after the initial 120-min monitoring period) and to the Principal Investigator, who will also be on call (if not present) during dosing sessions to coordinate responses to immediate needs or safety concerns. Staff in the psychopharmacology unit have substantial experience in supporting participants under altered states of consciousness, including in studies of DMT, psilocybin, ketamine, and nitrous oxide. We have also considered the possible adverse effects of participation in interviews and questionnaires. Interview procedures are unlikely to be distressing for this participant group, as they elicit beliefs and accounts of experiences expected to be familiar in professional practice (e.g., relationship with self, aspects of the self, and relational experiences). Psychodynamic psychotherapists routinely engage in self-reflection and discuss relationship patterns in supervision. In addition, their training typically involves long-term personal psychotherapy, which is likely to support self-awareness and resilience in exploring internal experience. Participants are therefore not expected to experience the interviews as unfamiliar or intrusive. In the RAP, participants will be able to identify target relational episodes independently and they will not be asked to disclose any identifiable details of those involved. Importantly, participants will not be asked to discuss sensitive topics or events or trauma content while under the influence of MDMA, and the interviewers will redirect to present-moment phenomenology if sensitive narratives emerge at that point. Despite these protections, participants will be provided with a mental health resource leaflet listing available supports should they require them after participation. Researchers will remain alert to signs of distress and will monitor participants throughout the study, offering support, advice, and signposting as needed. 2.9 Data management plan Data will be managed internally by the research team. A data monitoring committee is not required given that the study is not a clinical trial. Nonetheless, confidentiality is an overriding requirement and will be maintained according to rigorous institutional and national standards. Personally identifiable data will be collected during screening and stored on a secure institutional facility. These data will be destroyed when data collection is complete. Signed informed consent forms will be retained in a secure University-provided facility for three years after study completion. Pseudonymised interview transcripts, questionnaire data, and journal entries will be stored on access-controlled storage for three years following study completion. After this point, pseudonymised identifiers will be removed, and non-identifiable data will be retained indefinitely for study reporting and publication. Since the target sample belongs to a small local professional community, particular attention will be devoted to removing sections of the interviews that may indirectly identify participants from published interview quotes. Only researchers directly involved in the study and with approved General Data Protection Regulation (GDPR) training will have access to original data. Other researchers may be granted access in the future to data that can be fully anonymised. 2.10 Timeline The study has not generated results. Recruitment is expected to begin in the second quarter of 2026 and to be completed by the second or third quarter of 2027, with results available in 2028. 3. Discussion This protocol outlines a qualitative mechanistic study of the entactogen MDMA, which has shown promise in the treatment of PTSD. By combining phenomenological and thematic interviewing, RAP interviews with CCRT and reflective functioning scoring, longitudinal journaling, and psychological questionnaires, the study is designed to support a fine-grained mapping of experiential processes across acute, sub-acute, and integration phases. By purposively sampling trained psychodynamic psychotherapists and leveraging their clinical expertise and self-reflective capacities, we aim to interrogate psychological mechanisms that have been under-researched in neurobiologically focused studies, including changes in self-related processing, interpersonal patterns, reflective functioning, and meaning-making. This use of the first-person accounts of expert clinician-participants as high-fidelity reports for probing MDMA-related internal and relational phenomena is a distinctive feature of the protocol. The intended outcome is a theoretically grounded, testable model of MDMA’s psychological mechanisms of action, providing a bridge between first-person experience and constructs amenable to operationalisation in future clinical and experimental trials. We suggest that this methodological orientation adds value to the current research landscape by enabling a nuanced examination of psychological and interpersonal processes that are difficult to capture using standard quantitative and neuroscientific paradigms. Several features strengthen the study design. First, sequential, time-anchored interviews during dosing sessions prioritise experience-near description, while the subsequent IPA interview explicitly invites longer-term meaning-making. In this way, both immediate effects and the products of longer-term integration are captured. Second, triangulation across methods (phenomenological interviews, RAP interviews, narrative journals, and descriptive psychometrics) is intended to generate testable hypotheses and strengthen analytic validity. Third, focusing on psychodynamic clinicians maximises the sample’s information power [20]: participants’ training in introspection and in communicating complex psychological processes increases the likelihood of detailed, nuanced accounts, thereby enhancing the efficiency and depth of qualitative inference with a modest sample size. The study also has limitations. The open-label, non-controlled design means that expectancy and demand effects are likely to shape participants’ subjective experiences. Participants’ professional familiarity with psychotherapy processes and their theoretical commitments could both deepen insight into how MDMA achieves its effects and, conversely, constrain interpretation by privileging familiar explanatory frames over novel accounts. Our data is self-reported and is therefore vulnerable to memory and social desirability biases, despite efforts to capture in-the-moment experience. We seek to mitigate these limitations through: (i) phase-specific, idiographic analysis of interviews prior to cross-phase synthesis (2.6.1.A-C); (ii) triangulation across analysts at key stages (2.6.4); (iii) explicit attention to convergence and divergence during constant-comparison synthesis (2.6.4); and (iv) integration of experiential themes with structured indices, including CCRT and reflective functioning ratings (2.6.1.D). An additional limitation is that our participants will not be encouraged to engage with spontaneously emerging traumatic materials during the dosing sessions. Given that PTSD is the primary indication for MDMA-AP, this may limit the insights we can gain about changes in traumatic memories processing. However, the team considered it ethically problematic to encourage participants to engage with and discuss traumatic materials when they might not, ordinarily, be inclined to do so (i.e., outside of the MDMA state). Equally, avoiding trauma processing will enable us to preserve the interpretability of mechanisms because we will not be conflating drug effects with exposure-based therapeutic processes. Despite these constraints, we expect the study to contribute substantively to our understanding of MDMA as a therapeutic agent. A qualitative, mechanism-focused account of MDMA’s action may clarify which elements of adjunctive psychotherapy are necessary, for whom, and when, thereby supporting optimisation of psychotherapy principles and protocols. Candidate mechanisms – such as shifts in relational patterns and self–other representations, their hypothesised role, temporal ordering, and contextual conditions – can be formalised into hypotheses for experimental and clinical testing. Beyond MDMA, the protocol offers a transferable template for qualitative mechanistic examination of other psychedelic compounds, promoting the development of experience-led, evidence-based models of psychedelic-assisted therapies grounded in first-person phenomenology. Moreover, the primary output of this project – a theory (or theories) of psychological change induced by MDMA – may have implications beyond therapeutic refinement. For example, it may generate constructs and hypotheses that may inform the development of novel quantitative tools in behavioural psychopharmacology that draw on psychoanalytic concepts likely to be affected by MDMA (e.g., questionnaires or behavioural tasks assessing loosening of defences and access to previously repressed or suppressed material; ‘corrective emotional experiences’). Substantive amendments to the protocol will be reported transparently in subsequent publications. Such changes will be data-driven, agreed within the team, and submitted to the Research Ethics Committee for approval. Any pattern of adverse physiological or psychological events exceeding pre-specified thresholds (per our pre-specified procedure) will result in study interruption. In the event of early termination, we will document reasons and analyse accrued data with appropriate caveats. Dissemination plans include conference presentations and publication in peer-reviewed academic journals. 13 Apr 2026 -->PONE-D-26-08741-->-->Protocol for a qualitative mechanistic study of MDMA with a sample of psychoanalytic psychotherapists: a phenomenological investigation-->-->PLOS One Dear Dr. Kamboj Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would be grateful if you could address the comments raised by the two reviewers in Sections, 2, 3 and 6 of this email and the related attachments. Please submit your revised manuscript by May 28 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. --> If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Luca Aquili Academic Editor PLOS One Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions? The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses? The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable? Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Have the authors described where all data underlying the findings will be made available when the study is complete? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics. You may also provide optional suggestions and comments to authors that they might find helpful in planning their study. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: This paper describes a proposed study to characterize the psychological effects of MDMA in a sample of experienced psychoanalysts. The rationale for using this population is that they are expected to be uniquely attuned to psychological (emotional and relational) processes that may form the basis of the therapeutic value of MDMA in psychiatric treatment. The manuscript, and the protocol, have many strengths. The proposed study is clearly described, and it is carefully designed with appropriate outcome measures. The main claim of the paper is that this psychologically sophisticated sample of participants will provide new insights about how MDMA changes behavior in patients. Such new insights would be of great value to the discipline, as it struggles to identify processes and measures that mediate therapeutic benefits of psychedelic drugs. The doses, dosing interval, sample size, and broad range of outcome measures have been thoughtfully developed. The proposed outcome measures are appropriate in light of what is known from controlled MDMA studies so far, together with accumulated research on the processes involved in psychoanalytic or related psychiatric treatments. With a qualitative and descriptive study of this kind, there is no clear hypothesis, but the findings may provide the basis for developing operational measures in future studies. Here are some minor general comments and questions. One challenge in the field is to bridge the psychological processes involved in psychiatric treatments with the related neurobiological processes. Although both behavioral and pharmacological treatments have a place in treatment, it is difficult to harmonize their measures, mechanisms, and interactions. In a study like this one, using a drug with known receptor actions, it might be useful to identify psychological processes that have a plausible connection to known neurobiological underpinnings, for example those related to social attachment and bonding. This might include measuring heart rate variability or oxytocin levels. Does MDMA have similar effects in patients and healthy volunteers? If the patients’ psychiatric conditions alter the acute neural or psychological effects of the drug, then insights from even this highly sophisticated population might be of limited value. With this open label design, the participants prior expectancies are likely to affect their responses. Will the authors be able to compare directly the participants’ expected and actual responses to the drug? Might expectances differ in those who have or have not previously used the drug? Reviewer #2: I've uploaded my comments in a Word document with sections from the paper and then my comments afterwards. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: Yes: Richard Doblin, Ph.D. ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. --> Submitted filename: Bessels paper published.pdf Submitted filename: Grob PsychiatristsMDMA.pdf Submitted filename: lehrnerYehuda2026structured-protocols-in-mdma.pdf Submitted filename: My Comments on MDMA in psychoanalytic psychotherapists.docx 11 May 2026 Reviewer 1 We greatly appreciate the reviewer’s thoughtful comments and positive appraisal of our paper. We address their comments about limitations/challenges below. Response to specific comments: 1. One challenge in the field is to bridge the psychological processes involved in psychiatric treatments with the related neurobiological processes. Although both behavioral and pharmacological treatments have a place in treatment, it is difficult to harmonize their measures, mechanisms, and interactions. In a study like this one, using a drug with known receptor actions, it might be useful to identify psychological processes that have a plausible connection to known neurobiological underpinnings, for example, those related to social attachment and bonding. This might include measuring heart rate variability or oxytocin levels. RESPONSE: We thank the reviewer for highlighting this point. They are correct to notice that we do not use any objective behavioural or neurobiological indices relating to social behaviour. Although these might have been interesting additional measures, we deliberately concentrated our limited resources on prioritising high-quality qualitative data. Neurobiological assays are typically expensive and intrusive and are most informative in the context of well-powered experimental studies. Their use is also most justified when there are clear and specific hypotheses to test. In contrast our project is primarily concerned with *hypothesis generation*. Nonetheless, we recognise the value of such measures and look forward to applying them – especially in the context of dynamic therapeutic relationships – once our aspired-to psychodynamic model is developed and provides a basis for *hypothesis testing*. 2. Does MDMA have similar effects in patients and healthy volunteers? If the patients’ psychiatric conditions alter the acute neural or psychological effects of the drug, then insights from even this highly sophisticated population might be of limited value. With this open-label design, the participants' prior expectancies are likely to affect their responses. Will the authors be able to compare directly the participants’ expected and actual responses to the drug? Might expectances differ in those who have or have not previously used the drug? RESPONSE: The reviewer highlights an important point that requires clarification. Because our study is not examining the effects of MDMA on psychopathology per se, this limitation is less of a concern for us. To reiterate, our primary goal is to use insights from psychotherapists to improve our understanding of MDMA’s potential mechanisms of action as a treatment. This, we believe, does not rely on overlapping neural or psychological processes between psychotherapists and those with psychiatric conditions. Nonetheless, because of the expert status of our participants, we fully expect them to be able to translate their insights to normal and abnormal psychological processes. Regarding comparisons between those with/without previous experience of MDMA/psychedelics, this is not an explicit aim of the project. However, participant characteristics, including past exposure, will be reported transparently and considered as part of the whole interpretative ‘story’. We believe that considerations of context (including past exposure) will provide an opportunity to ‘thicken’ our description of participants’ experiences rather than provide a basis for direct comparisons between groups. Regarding expectancy effects, we now clarify in the discussion that these are examined as part of our phenomena of interest, and we will examine how participants’ prior beliefs intereact with their actual MDMA experience to influence meaning-making. Both of reviewer 1’s points made us consider whether we had been clear enough at the early stages of the paper to highlight the unique methodological approach we are taking. We therefore further foreground our approach by adding a sentence at the start of the ‘Discussion’ section of the Abstract to highlight our distinctive first-person emphasis in a specially selected participant group. Reviewer 2 As above we greatly appreciate the encouraging and thoughtful comments of the reviewer. 1. The FDA Advisory Committee and the FDA’s most crucial critique was about functional unblinding, not about the psychotherapy+ MDMA design. FDA doesn’t regulate psychotherapy but as part of FDA’s Risk Evaluation and Mitigation Strategies (REMS), it can regulate having a licensed therapist in the room when MDMA is administered. The FDA can also require certain Furthermore, FDA doesn’t need to determine whether psychotherapy is necessary for clinical benefits, that’s too simplistic since administering MDMA outside of a therapeutic context is not what’s being asked to be approved. There are also ethical issues from giving moderate to severe PTSD patients MDMA without any therapeutic support, people could be worse off. RESPONSE: We thank the reviewer for highlighting this. We have now corrected the relevant section of the introduction. 2. It’s overstated that without a well-developed understanding of MDMA’s psychological mechanisms of action, it’s not possible to study non-pharmacological elements like different psychotherapeutic approaches. …. RESPONSE: We agree with the reviewer. We believe that his concern relates primarily to our strong statement that “….it is not possible…..”. We have softened this definitive statement by replacing the “it is not possible” phrase with “it is difficult to establish….” 3. a. One week apart or more feels too soon. I suggest two weeks minimum between sessions for participants to learn more about the integration process, three to four weeks is even better. RESPONSE: We agree with the reviewer that longer intervals between sessions would have been ideal. The minimum of one week was informed by stakeholder consultation which emphasised the importance of flexibility in scheduling sessions. However, while this relatively short interval applies to the two dosing sessions, there are still substantial opportunities for longer-term integration processes to occur between the second dosing session and the two follow-up sessions. b. What is “safety-oriented support” and how does it differ from Inner-Directed Therapy? If the therapists in this study don’t facilitate the experiential processing of emotion and memory, how will the already overly cognitive psychoanalytic psychotherapists get embodied insights into MDMA’ mechanisms of action? RESPONSE: In relation to the ‘safety-oriented support’ phrase, we agree its meaning is opaque. We have therefore removed this phrase completely, and instead provide a more detailed and specific outline of the nature of the interaction between researcher and participant, and clarify its limited resemblance to ‘inner directed therapy’. c. You could consider adding some somatic therapists experienced in treating trauma to see what additional insights they might provide. RESPONSE: Regarding other modalities (e.g., somatically focused therapies), although this would generate interesting and varied responses, it would be counterproductive from a ‘saturation’ perspective, which demands that such heterogeneity be minimised. This is not to say that sensory aspects of the experience will be ignored in the interviews. Indeed, it would be especially interesting if sensory and somatic aspects of the experience predominate despite the typical ‘mentalising bias’ of psychoanalytically trained therapists. Such experiences viewed through a psychoanalytic lens, we believe, would provide opportunities for novel discoveries that are less likely to occur in therapists already primed to conceptualise MDMA’s effects from a somatic perspective. 4. Why upper age limit? FDA has no upper age limit. RESPONSE: We do not believe there is sufficient evidence to strongly justify any upper (or indeed, lower) age limit for MDMA. As such, any age limit can be argued to be arbitrary. We chose 65 as the ‘traditional’ cutoff separating middle and older age. Since cardiovascular disease increases with age, the risks of cardio-related adverse effects would likely also increase with age given MDMA well-established effects on heart rate and blood pressure. Given that ours is a non-clinical study, an overriding priority is participant safety, especially given that risks are not counterbalanced by any therapeutic benefits to participants. 5. Dose feels too low. There are two MDMA sessions. The first could be 80 mg followed two hours later by 40 mg. The second session could be 120 mg following by 40 or 80- I suggest 80. RESPONSE: Although we agree that our proposed dosing is on the lower end of the dosing spectrum, the final dose was decided upon after thorough review of the literature, extended internal discussion within the expert team - which consists not only of leading MDMA psychopharmacologists, but also an ethicist – as well as consultation with external MDMA experts and stakeholders (psychoanalytic psychotherapists). Based on these, a maximum dose of 120 mg was deemed to appropriately balance the goal of generating the pharmacological signal of interest, while minimising the potential for significant residual symptoms. The latter was especially important in a clinician group who have ongoing patient responsibilities. We have how included an explanation of this under section 2.7. 6. What about positive adverse events, they should also be gathered. RESPONSE: Although we do not conceptualise these as “positive adverse events”, we assess compassion, empathy, (epistemic) trust and positive affect (outlined in Section 2.5.2). We now also include ‘emotional breakthrough’ in our inventory of ‘positive effects’. As such, we believe there is sufficient coverage in our assessments of adverse, as well as positive, effects of MDMA. 7. It would be useful to consider adding some measures of psychological mechanisms of action added to the Phase 3 study design by Bessel van der Kolk, as reported in the attached paper. Below are the measures he used. Also attached is a 1992 paper by Dr. Charles Grob about the reflections of 20 psychiatrists on their MDMA experiences, with the abstract below. RESPONSE: We thank the reviewer for this helpful suggestion. Our series of quantitative assessments already includes a number of relevant psychological constructs, including (like van der Kolk) self-compassion. However, our assessment is more inclusive than van der Kolk’s as it also incorporates ‘other-compassion’. Given our study goals (which do not relate to treating psychopathology), our measures are all tightly organised around themes relating to mentalising, trust, and attachment bonding. Given this, and given the nature of our participant group, we included several additional ‘mechanistic’ measures after piloting, relating to self-relating (other than self-compassion), ‘emotional breakthrough’ (potentially conceptualised psychoanalytically as ‘abreaction’, ‘catharsis’ or emotional insight), response to the psychedelic experience (altered consciousness and challenging experiences), as well as participants’ response to music. 8. This may limit participants’ understanding of how MDMA impacts the experience and processing of traumatic memories. RESPONSE: We agree that this aspect of our protocol may limit participants’ understanding of how MDMA specifically affects trauma memories. We have now included a section in the discussion that highlights this limitation. 9. Not clear this will be accomplished if subjects are redirected from engaging with traumatic memories. RESPONSE: As the reviewer will know, MDMA’s applications extend beyond PTSD treatment (e.g. social anxiety, alcohol use, and autism spectrum disorder). As such, we do not see the lack of trauma focus in our study to be especially problematic when considered alongside the potential of MDMA to treat a variety of non-trauma-related disorders. As such, we believe it is indeed realistic that our research will help us clarify “which elements of adjunctive psychotherapy are necessary, for whom, and when, thereby supporting optimisation of psychotherapy principles and protocols”. 10. This is a fascinating study that should take place. RESPONSE: We greatly appreciate Dr Doblin’s kind encouragement and look forward to presenting our findings to the broader MDMA/psychedelics research community in due course. Submitted filename: Response to Reviewers.docx 19 May 2026 Protocol for a qualitative mechanistic study of MDMA with a sample of psychoanalytic psychotherapists: a phenomenological investigation PONE-D-26-08741R1 Dear Dr. Kamboj, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Luca Aquili Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions? The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.--> Reviewer #2: Yes ********** -->2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses? The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.--> Reviewer #2: Yes ********** -->3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable? Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.--> Reviewer #2: Yes ********** -->4. Have the authors described where all data underlying the findings will be made available when the study is complete? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #2: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #2: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics. You may also provide optional suggestions and comments to authors that they might find helpful in planning their study. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #2: I'm fine with the paper being published as is with no further changes. However, I am unpersuaded by several responses to my comments in my previous review. There is sufficient cardiovascular screening to enroll people over age 65, with that age limit potentially excluding some of the most experienced psychodynamically trained psychotherapists. The doses of MDMA, 80 mg followed by 40 mg, are lower than used in most therapy research which often includes doses of 120 mg followed by 60 mg, and thus the study may miss gathering some fundamentally important data. The idea that it's important to avoid "a rapid peak effect (as might be expected from a 120 mg bolus)" is not based on data and is not a significant factor in generating adverse events. I suggest giving subjects the option to increase the dose in their second experience to 120 mg followed by 40 mg (or if you are really bold, followed by 80 mg. I also am unpersuaded that dosing people one week apart is a good idea "to provide greater flexibility to participants." The idea that the participants should be able to get back to work with their patient responsibilities further limits the data that can be gathered. If the subjects are not wanting to let the experience deepen since they think they need to be ready to see patients the next day or in two days, the experience can be more superficial. (I hope the participants are being instructed that they should have no responsibilities the day after the MDMA experience, and if they need more time to integrate, they should have a plan for a colleague to take over for them till they feel grounded again). I am profoundly unpersuaded that if participants start to process prior traumas, that they should be redirected to "to present moment phenomenology if sensitive narratives emerge..." The authors of the paper make a big deal about how experienced psychodynamically trained psychotherapists are able to understand and describe their internal states and understand about transference and countertransference. The fear that such experienced psychotherapists would be destabilized by addressing their own trauma is contradicted by their supposed experience with their own psychotherapy of several times a week for several years. The paper says, "the team considered it ethically problematic to encourage participants to engage with and discuss traumatic materials when they might not, ordinarily, be inclined to do so (i.e. outside of the MDMA state)".Has the team considered the ethical problems in having participants recall traumatic memories under the influence of MDMA and then being redirected away from those memories? The paper says, "Equally, avoiding trauma processing will enable us to preserve the interpretability of mechanisms because we will not be conflating drug effects with exposure-based therapeutic processes". What this avoidance can miss is that MDMA's drug effects help people engage with "exposure-based therapeutic processes." The US Dept. of Defense has funded a $4.9 million study to examine combining MDMA with Prolonged Exposure,specifically to look at how MDMA drug effects can potentially aid in "exposure-based therapeutic processes." Pilot studies have already demonstrated that MDMA can help subjects engage with PE, when without MDMA about 50% of subjects drop out of PE (and also CPT). The paper also says, "As the reviewer will know, MDMA’s applications extend beyond PTSD treatment (e.g. social anxiety, alcohol use, and autism spectrum disorder). As such, we do not see the lack of trauma focus in our study to be especially problematic when considered alongside the potential of MDMA to treat a variety of non-trauma-related disorders" . As the authors should know, in the study in England looking into MDMA-assisted therapy to treat AUD, most of the participants ended up dealing with unprocessed trauma that led them to run away from their emotions with alcohol. Society anxiety is often connected to various fears and sometimes past traumas so the idea that only PTSD is based on trauma is fundamentally wrong. This is a fascinating study that I worry will not generate as rich of a data set as it could, due to several risk-averse decisions and trade-offs. Still, I'm highly supportive of this study and this paper. I've attached a paper by Amy Lerner and Rachel Yehuda about the trade-offs between patient-centered therapies and structured therapies like PE and CPT and CBT. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #2: Yes: Richard Doblin ********** Submitted filename: lehrnerYehuda2026structured-protocols-in-mdma.pdf PONE-D-26-08741R1 PLOS One Dear Dr. Kamboj, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Luca Aquili Academic Editor PLOS One